Tocilizumab in glucocorticoid-naïve large-vessel vasculitis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.75, 2013, Pages

  Pazzola, G ^a   Padovano, I ^a   Boiardi, L ^a   Versari, A ^b   Pipitone, N ^a   Catanoso, M ^a   Pulsatelli, L ^c   Meliconi, R ^c   Salvarani, C ^b  

^a Rheumatology Unit   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Interleukin 6; Interleukin 6 receptor; Large vessel vasculitis; Tocilizumab

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOCORTICOID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; TOCILIZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CASE REPORT; CLAUDICATION; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE MARKER; DRUG CONTRAINDICATION; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; VASCULITIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME; VASCULITIS;

EID: 84878417502     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. PROVEN A, GABRIEL SE, ORCES C, O'FALLON WM, HUNDER GG: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Artrhitis Rheum 2003; 49: 703-8.
2. MARTINEZ-LADO L, CALVIñDíAZ-O C, PIñEIRO A et al.: Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 2011; 90: 186-93.
3. SALVARANI C, PIPITONE N: Treatment of large-vessel vasculitis: where do we stand? Clin Exp Rheumatol 2011; 29 (Suppl. 64): S3-5.
4. HOFFMAN GS, LEAVITT RY, KERR GS, ROTTEM M, SNELLER MC, FAUCI AS: Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.
5. HOFFMAN GS, CID MC, RENDT-ZAGAR KE et al.: Infliximab for maintenance of glucocorticosteroid- induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30.
6. SEILTZ M, REICHENBACH S, BONEL HM, ADLER S, WERMELINGER F, VILLIGER PM: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141:w13156.
7. SALVARANI C, MAGNANI L, CATANOSO M et al.: Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
8. KERR GS, HALLAHAN CW, GIORDANO J et al.: Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
9. MISHRA R, DANDA D, JAYASEELAN L SIVAKUMAR R, LAWRENCE A, BACON PA: ITAS & DEI.TAK-scores for clinical disease activity and damage extent in Takayasu's aortoarteritis (TA). Rheumatology (Oxford) 2008; 47 (Suppl. 2): 101.
10. NISHIMOTO N, TERAO K, MIMA T, NAKAHARA H, TAKAGI N, KAKEHI T: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64.